Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

Michele B. Kaufman, PharmD, BCGP  |  Issue: February 2022  |  December 9, 2021


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Highlights of prescribing information: Actemra (tocilizumab). U.S. Food & Drug Administration. 2021 Mar 4.
  2. Ahn S, Oh J, Heo H, et al. Flare after switching from intravenous tocilizumab to subcutaneous formulation in patients with rheumatoid arthritis [abstract: 0836]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).
  3. BLA approval. BL 125276. (Tocilizumab (Actemra): FDA approval letter.) U.S. Food & Drug Administration. 2010 Jan 8.
  4. BLA approval. BLA 125472/0. (Tocilizumab (Actemra) solution for subcutaneous injection: FDA approval letter.) 2013 Oct 21.

Page: 1 2 | Single Page
Share: 

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAIV tocilizumabRA flaressubcutaneous tocilizumabtocilizumab

Related Articles

    FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD

    March 25, 2021

    Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.

    Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients

    May 23, 2022

    In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…

    FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA

    June 9, 2017

    Due to possible heart-related side effects, romosozumab is no longer expected to be approved this year for the treatment of osteoporosis…

    FDA Approves Subcutaneous Tocilizumab for Ages 2–17

    October 29, 2018

    The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences